NCT02808793View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK002

PHASE1CompletedINTERVENTIONAL

Enrollment

25

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

December 31, 2018

Study Completion Date

December 31, 2018

Conditions

Indolent Systemic Mastocytosis

Interventions

DRUG

AK002

Trial Locations (1)

Unknown

Charité - Universitätsmedizin Berlin, Berlin

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Allakos Inc.

INDUSTRY

NCT02808793 - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK002 | Biotech Hunter | Biotech Hunter